PoliticsUS panel warns of China’s biotech rise, fuelling push to curb ties as Chinese firms remain unfazed
Analysts say fresh warnings from a US congressional advisory body about China’s fast-growing biopharmaceutical sector are adding momentum to Washington’s efforts to limit cross-border ties, while China’s industry appears largely unmoved. The body said China was gaining a competitive advantage and that Western firms increasingly pay large upfront fees to license Chinese drugs as its innovation capacity grows.
US panel warns of China’s biotech rise, fuelling push to curb ties as Chinese firms remain unfazed
Politics